Actualités

As Legend’s LB2102 trial in SCLC fails to dazzle, co-developer Novartis banks on quick manufacturing to find a commercial edge.

AMGN wins EU approval for Imdylltra in extensive-stage small cell lung cancer after phase III data showed a 40% reduction in death risk.

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. TScan Therapeutics, Inc. (NASDAQ:TCRX) is one of the most popular penny stocks. TheFly reported on May 6 that TCRX announced its first-quarter 2026 financial results, covering the period ended March 31, 2026, along with a corporate update. The […]

Gilead Sciences has outperformed other healthcare stocks, and analysts remain highly optimistic about the stock’s outlook

Despite Vertex Pharmaceuticals' underperformance relative to the healthcare sector over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

The group has been funding research projects, touring factories and piloting workforce development programs. Its three co-directors shared highlights during recent events in Boston and Cambridge.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Amgen's fair value estimate has been nudged from US$349.66 to US$352.23 per share, a small move that still matters if you are tracking entry points and valuation ranges. Around that level, analysts are split, with some using higher targets such as US$427 on the back of rare disease and pipeline assets, while others sit closer to US$350 and stress that recent gains already price in a lot of the good news. Read on to see how to interpret these shifting targets and keep up with the evolving...

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

Despite Amgen's outperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Merck & Co. has surged past the S&P 500 Index over the past year, and analysts remain somewhat optimistic about the stock’s growth potential.

Over the past year, many Amgen Inc. ( NASDAQ:AMGN ) insiders sold a significant stake in the company which may have...

Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.

NVO and AMGN square off as GLP-1 leadership, pipeline depth and diversification shape a compelling healthcare stock comparison.

RTX builds a $271B backlog on defense demand and recovering air travel, but tariffs and supply-chain issues cloud growth.

The Dow gave back its opening gains, with healthcare stocks a big drag. The blue-chip index was trading flat, while the S&P 500 was up 0.9%, and the Nasdaq rose 1.4%. UnitedHealth Group and Amgen, among the Dow's top five stocks, were down by nearly 3% and 0.4%, respectively.

Amgen faces LOE headwinds and pricing pressure, yet key growth drugs and biosimilars continue gaining traction.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.

(Bloomberg) -- Quantinuum Inc., a quantum computing company backed by Honeywell International Inc., is seeking to raise $1.05 billion in its US initial public offering, capitalizing on investor enthusiasm for the technology. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inc

The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.

Amgen Inc. (NASDAQ:AMGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Amgen announced the retirement of its Executive Vice President and Chief Financial Officer, Peter Griffith, who has held the role since 2020. During his tenure, Griffith was instrumental in strengthening the company’s financial position, supporting capital allocation, and […]

Amgen stock could offer attractive long-term upside for investors willing to ride through near-term volatility.

Amgen names a new chief financial officer, Thales hires Nissan’s former CFO and Rent the Runway’s finance chief tenders his resignation.

Amgen (AMGN) stock is in focus after safety concerns around its rare disease therapy Tavneos, including reported patient deaths in Japan, prompted regulators and partners to restrict new prescriptions and consider withdrawal in the U.S. See our latest analysis for Amgen. At a share price of $337.42, Amgen has seen its 90 day share price return fall 9.96%, even as its 1 year total shareholder return of 27.83% and 3 year total shareholder return of 70.14% point to stronger longer term...

Thomas Dittrich is the latest “boomerang” executive to return to a former employer as CFO. Over a decade ago he was the biotech company’s chief accountant.

The Japanese drugmaker that sells rare-disease medicine Tavneos said new patients will be able to get the drug, which carries risk of liver injury.

Amgen Inc. (NASDAQ:AMGN) is one of Louis Navellier’s top long-term stock picks. On May 14, Piper Sandler reiterated an Overweight rating on Amgen Inc. (NASDAQ:AMGN) but lowered the price target to $427 from $432. The new price target still represents significant upside potential as the research firm expects the company to deliver top-line revenue growth […]

Nvidia’s backing highlights growing confidence in AI-powered biotech stocks.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.